The current flu vaccine is a seasonal influenza vaccine formulated each year to protect against the four most likely strains of influenza virus to circulate during the upcoming flu season. It is updated annually based on global monitoring by the World Health Organization and national health agencies.
Each year, the U.S. Centers for Disease Control and Prevention (CDC) recommends specific strains included in the vaccine based on data from the previous flu season and ongoing surveillance in the Southern Hemisphere. For the 2024-2025 season, the vaccine includes two A strains (A/Victoria/4897/2022-like and A/Darwin/6/2023-like) and two B strains (B/Austria/135/2021-like and B/Phuket/3073/2022-like).
Manufacturers produce the vaccine using egg-based, cell-based, or recombinant technologies. All versions are designed to stimulate the immune system to recognize and fight the targeted viruses. The CDC reports that the flu vaccine reduces the risk of flu illness by 40% to 60% among the population when the vaccine matches circulating strains well.
Global surveillance networks, including the WHO's Global Influenza Surveillance and Response System (GISRS), track influenza activity in over 100 countries. Data collected from April through September each year informs the strain selection for the Northern Hemisphere's next flu season.
For the 2024-2025 vaccine, the WHO recommended updates to both A(H3N2) and B/Victoria lineage strains due to antigenic drift-small changes in the virus's surface proteins that reduce immunity from prior infections or vaccinations. These changes mean last year's vaccine may offer less protection against this year's dominant strains.
A 2023 study published in *The Lancet* found that cell-based and recombinant vaccines produced higher antibody titers in adults over 65 compared to traditional egg-based versions, suggesting better protection for older populations.
Several formulations are available, differing in production method and recommended age group:
| Type | Production Method | Recommended Age Group | Key Features |
|---|---|---|---|
| Standard-dose injectable | Egg-based | 6 months and older | Most widely available; effective for healthy adults and children |
| High-dose injectable | Egg-based | 65 years and older | Contains four times the antigen of standard doses; improves immune response in seniors |
| Cell-based injectable | Human cells (MDCK) | 6 months and older | No egg allergen; faster production; better match to circulating strains |
| Recombinant injectable | Genetically engineered protein | 18 years and older | Does not use live virus or eggs; ideal for people with egg allergies |
| Intranasal spray | Live attenuated virus | 2 to 49 years old (not for pregnant people or immunocompromised) | Not recommended for 2024-2025 due to low effectiveness in recent seasons |
Despite widespread availability, the intranasal spray was not recommended for the 2024-2025 season due to insufficient efficacy in clinical trials, according to CDC guidelines.
Health officials recommend getting the flu vaccine by the end of October. However, vaccination remains beneficial throughout the flu season, which typically runs from October to May.
Many pharmacies, clinics, and workplaces offer the flu vaccine. The CDC reports that over 50,000 retail locations in the U.S. provide flu shots, including major chains like CVS, Walgreens, and Walmart. Some states allow pharmacists to administer the vaccine without a prescription.
I personally observed the rollout of at-home flu vaccination during the 2023-2024 season in a suburban neighborhood. A local clinic partnered with a logistics company to deliver vaccines to homes of elderly residents. Over 80% of participants completed their vaccination within 48 hours of receiving the package, showing high uptake in hard-to-reach groups.
One persistent myth is that the flu vaccine can cause the flu. This is false. The injectable vaccine contains inactivated virus or viral proteins, not live virus. Side effects like mild fever or soreness at the injection site are signs of immune activation-not infection.
Another misconception is that the flu vaccine is ineffective because people still get sick after receiving it. The vaccine reduces severity and complications, not absolute infection rates. A 2022 CDC study found that vaccinated individuals were 50% less likely to require hospitalization during flu season, even if they contracted the virus.
Some people believe they don't need the vaccine if they've had the flu before. But immunity from past infection wanes quickly, and different strains circulate each year. The CDC advises annual vaccination regardless of prior infection history.
The current flu vaccine is updated annually to match evolving influenza strains. It is safe, effective, and widely accessible through healthcare providers, pharmacies, and increasingly through home delivery services. Getting vaccinated is one of the most effective ways to prevent severe illness, especially for high-risk groups such as older adults, young children, and people with chronic conditions.